AU2001255114A1 - Preparation for the prevention and/or treatment of vascular disorders - Google Patents
Preparation for the prevention and/or treatment of vascular disordersInfo
- Publication number
- AU2001255114A1 AU2001255114A1 AU2001255114A AU5511401A AU2001255114A1 AU 2001255114 A1 AU2001255114 A1 AU 2001255114A1 AU 2001255114 A AU2001255114 A AU 2001255114A AU 5511401 A AU5511401 A AU 5511401A AU 2001255114 A1 AU2001255114 A1 AU 2001255114A1
- Authority
- AU
- Australia
- Prior art keywords
- fraction
- prevention
- treatment
- vascular disorders
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 210000003918 fraction a Anatomy 0.000 abstract 1
- 210000000540 fraction c Anatomy 0.000 abstract 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 235000001055 magnesium Nutrition 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 150000003905 phosphatidylinositols Chemical class 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 235000016804 zinc Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56638600A | 2000-05-08 | 2000-05-08 | |
US09/566,386 | 2000-05-08 | ||
US09/703,798 | 2000-11-02 | ||
US09/703,798 US7226916B1 (en) | 2000-05-08 | 2000-11-02 | Preparation for the prevention and/or treatment of vascular disorders |
PCT/NL2001/000347 WO2001084961A2 (en) | 2000-05-08 | 2001-05-08 | Preparation for the prevention and/or treatment of vascular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001255114A1 true AU2001255114A1 (en) | 2001-11-20 |
Family
ID=27074171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001255114A Abandoned AU2001255114A1 (en) | 2000-05-08 | 2001-05-08 | Preparation for the prevention and/or treatment of vascular disorders |
Country Status (13)
Country | Link |
---|---|
US (5) | US7226916B1 (de) |
EP (5) | EP2292210A1 (de) |
CN (1) | CN1245984C (de) |
AT (2) | ATE431133T1 (de) |
AU (1) | AU2001255114A1 (de) |
CA (1) | CA2408032C (de) |
CY (3) | CY1107237T1 (de) |
DE (2) | DE60132081T2 (de) |
DK (3) | DK1282365T3 (de) |
ES (3) | ES2533362T7 (de) |
HK (1) | HK1052439B (de) |
PT (3) | PT2070519E (de) |
WO (1) | WO2001084961A2 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0951842B1 (de) * | 1999-01-20 | 2002-12-04 | N.V. Nutricia | Säuglingsnährpräparat |
US7208180B2 (en) | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
KR100680121B1 (ko) * | 2001-08-09 | 2007-02-07 | 데구사 푸드 인그리디언츠 게엠베하 | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
DE10250727B4 (de) * | 2002-04-19 | 2008-07-10 | Cargill, Incorporated, Wayzata | Matrix mit einer bioaktiven Phospholipid-haltigen Komponente |
DE10217555A1 (de) * | 2002-04-19 | 2004-02-19 | Degussa Bioactives Deutschland Gmbh | Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix |
DE10217557A1 (de) * | 2002-04-19 | 2003-11-06 | Degussa Bioactives Gmbh | Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix |
WO2003088949A2 (de) * | 2002-04-19 | 2003-10-30 | Bioghurt Biogarde Gmbh & Co. Kg. | Matrix mit einer bioaktiven phospholipid-haltigen komponente |
AU2003229993B2 (en) * | 2002-05-03 | 2008-07-24 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
BRPI0311909A8 (pt) | 2002-06-19 | 2018-02-06 | Nutricia Nv | Métodos para a manufatura de uma composição, e para aumentar a capacidade de metilação de um indivíduo, e, composição farmacêutica ou nutricional |
EP1388295A1 (de) * | 2002-08-07 | 2004-02-11 | Nestec S.A. | DHA-enthaltendes Nahrungsmittel auf Getreidebasis |
FR2847472B1 (fr) * | 2002-11-22 | 2006-08-11 | Synergia | Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires |
CN100462080C (zh) * | 2003-02-05 | 2009-02-18 | 努特里奇亚有限公司 | 用于预防和/或治疗脓毒症的肠内组合物 |
BRPI0409585A (pt) * | 2003-04-17 | 2006-04-18 | Boehringer Ingelheim Int | suplemento multivitamìnico e mineral para mulheres grávidas |
US8703209B2 (en) | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
EP1637134A4 (de) * | 2003-06-20 | 2010-01-27 | Mochida Pharm Co Ltd | Zusammensetzung zur prävention/behandlung von varizen |
EP1643863A2 (de) * | 2003-07-10 | 2006-04-12 | Carl A. Forest | Nahrungsmittel, getränke, würzmittel, gewürze und salatsaucen mit spezialzusätzen |
US8017160B2 (en) * | 2003-08-15 | 2011-09-13 | Russell Jaffe | Enhancement of magnesium uptake in mammals |
DE10340740A1 (de) * | 2003-09-04 | 2005-03-31 | Degussa Food Ingredients Gmbh | Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis |
IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US20050130937A1 (en) | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
EP1645276A1 (de) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Behandlung von neurodegenerativen Erkrankungen |
US20090054523A1 (en) * | 2005-01-24 | 2009-02-26 | Morten Bryhn | Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases |
HUE031206T2 (en) * | 2005-05-23 | 2017-06-28 | Massachusetts Inst Technology | Formulations and methods of application containing PUFA |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
WO2007045407A2 (en) * | 2005-10-18 | 2007-04-26 | Artmed S.R.L. | Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma |
US10238599B2 (en) | 2006-01-19 | 2019-03-26 | The Regents Of The University Of Michigan | Composition and method for treating congenital cytomegalovirus induced hearing loss |
US8338397B2 (en) | 2006-01-19 | 2012-12-25 | The Regents Of The University Of Michigan | Composition and method of treating side effects from antibiotic treatment |
US7951845B2 (en) | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
US9770433B2 (en) | 2006-01-19 | 2017-09-26 | The Regents Of The University Of Michigan | Composition and method for treating tinnitus |
USRE46372E1 (en) | 2006-01-19 | 2017-04-25 | The Regents Of The Univerity Of Michigan | Method for treating hearing loss |
US8927528B2 (en) | 2006-01-19 | 2015-01-06 | The Regents Of The University Of Michigan | Composition for treating hearing loss |
US9919008B2 (en) | 2006-01-19 | 2018-03-20 | The Regents Of The University Of Michigan | Method for treating age-related hearing loss (ARHL) |
US9889156B2 (en) | 2006-01-19 | 2018-02-13 | The Regents Of The University Of Michigan | Method for treating noise-induced hearing loss (NIHL) |
US8871808B2 (en) | 2006-06-22 | 2014-10-28 | Ben-Gurion University Of The Negev Research And Development Authority Et Al. | Over-production of dihomo linolenic acid by a mutant strain of Parietochloris incisa |
CA2657748C (en) * | 2006-07-14 | 2014-10-21 | Nattopharma Asa | Pharmaceutical and nutraceutical products comprising vitamin k2 |
KR101578498B1 (ko) | 2006-12-28 | 2015-12-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
AU2008269728B2 (en) | 2007-06-26 | 2013-10-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
WO2009082203A1 (en) | 2007-12-20 | 2009-07-02 | N.V. Nutricia | Liquid nucleotides/nucleosides-containing product |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
EP2179046B1 (de) * | 2007-08-13 | 2013-01-02 | Ben-Gurion University of the Negev Research and Development Authority | Überproduktion von dihomo-gamma-linolensäure durch einen parietochloris incisa-mutantenstamm |
DE102007042557A1 (de) * | 2007-09-07 | 2009-03-19 | Membramed Gmbh | Neuartige Formulierung von Phospholipiden |
CA2702577A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
US20100323028A1 (en) * | 2007-11-30 | 2010-12-23 | Jbs United, Inc. | Method and composition for treating pulmonary hemorrhage |
US9034399B2 (en) * | 2008-01-03 | 2015-05-19 | Melaleuca, Inc. | Dietary compositions for promoting brain health |
AU2009219050B2 (en) * | 2008-02-29 | 2014-04-24 | Biolab Sanus Farmaceutica Ltda. | Pharmaceutical composition comprising racetam and carnitine and process for its preparation |
EP2172203A1 (de) * | 2008-09-17 | 2010-04-07 | Giuliani S.P.A. | Pharmazeutisches Zusammensetzung zur Behandlung von Magen-Darm-Reizungsstörungen |
US9308261B2 (en) * | 2008-10-13 | 2016-04-12 | Pregnant Princess & Co. Ltd. | Compositions and methods for treating varicose veins |
US9062275B2 (en) * | 2009-04-17 | 2015-06-23 | Natac Pharma, S.L. | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
WO2011066471A1 (en) | 2009-11-25 | 2011-06-03 | Loma Linda University Medical Center | Chitosan-based hemostatic textile |
AU2011315537A1 (en) * | 2010-10-12 | 2013-05-02 | Vifor Sa | Novel omega-3 and omega-6 fatty acid compositions and uses thereof |
ES2627342T3 (es) | 2011-07-12 | 2017-07-27 | Foodchek Systems, Inc. | Medio de cultivo, método para cultivar Salmonella y E. coli y método para detectar Salmonella y E. coli |
RU2505290C2 (ru) * | 2011-10-31 | 2014-01-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Фармацевтическая композиция, обладающая свойством снижения эндотелиальной дисфункции при заболеваниях сердечно-сосудистой системы |
WO2013138368A1 (en) * | 2012-03-12 | 2013-09-19 | Loma Linda University Medical Center | Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases |
CN103432156A (zh) * | 2013-08-30 | 2013-12-11 | 深圳奥萨医药有限公司 | ω-3脂肪酸和B族维生素的药物组合物及其用途 |
GB201405033D0 (en) | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
DE202014102551U1 (de) * | 2014-05-30 | 2015-02-26 | Orthomol Pharmazeutische Vertriebs Gmbh | Diätetische Zubereitung in Form eines Riegels |
US10183044B2 (en) | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
DK3328214T3 (da) | 2015-07-29 | 2020-04-27 | Abbott Lab | Ernæringsprodukter med forbedret lipofil opløselighed og biotilgængelighed i en let blandbar form |
CN105079009B (zh) | 2015-08-25 | 2018-05-01 | 厦门金达威生物科技有限公司 | 预防和/或治疗心脑血管疾病的组合物 |
CN107252089A (zh) * | 2017-04-05 | 2017-10-17 | 吉林省润生特膳食品科技开发有限公司 | 一种山楂桃仁山药粉及其制备方法 |
AU2018390261B2 (en) | 2017-12-21 | 2023-03-16 | Nippon Zoki Pharmaceutical Co., Ltd. | Agent for treatment of nervous system disease |
CN110404049A (zh) * | 2019-07-23 | 2019-11-05 | 张明 | 通过雾化吸入防治心脑血管病和老年痴呆的组合物及应用 |
FR3099339B1 (fr) * | 2019-08-01 | 2022-06-17 | Specialites Pet Food | Hydrolysat protéique issu de poissons bleus |
CN112843072A (zh) * | 2021-01-12 | 2021-05-28 | 山东省科学院生物研究所 | 磷脂在调控血管生成方面的应用 |
CN113456640A (zh) * | 2021-08-26 | 2021-10-01 | 烟台大学 | 石杉碱甲在心肌缺血损伤预防中的应用 |
AU2022345465A1 (en) | 2021-09-17 | 2024-03-21 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
IT202200010583A1 (it) * | 2022-05-23 | 2023-11-23 | Neilos S R L | “Composizione nutraceutica o farmaceutica per l’infertilità maschile” |
GB202209414D0 (en) * | 2022-06-27 | 2022-08-10 | Aker Biomarine Antarctic As | Uses for phospholipid compositions |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2824362A1 (de) | 1978-06-01 | 1979-12-13 | Josef Dipl Chem Dr Rer N Klosa | Pharmazeutisches praeparat mit l-tryptophan |
IT1212900B (it) * | 1983-11-17 | 1989-11-30 | Valle Francesco Della | Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna |
NO862999L (no) | 1985-07-26 | 1987-01-27 | Yeda Res & Dev | Lipidblanding for membranfluidisering. |
US4897380A (en) | 1985-08-30 | 1990-01-30 | Pollack Robert L | Method and composition for relieving dietary-related disorders |
US5177082A (en) * | 1985-11-05 | 1993-01-05 | Yu Chao Mei | Huperzines and analogs |
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
JPS63208524A (ja) | 1987-02-25 | 1988-08-30 | Nippon Oil & Fats Co Ltd | 睡眠リズム改善剤 |
AU1790988A (en) | 1987-05-19 | 1988-12-21 | Baylor College Of Medicine | Phosphoethanolamine for treatment of alzheimer's disease |
WO1989002737A1 (en) | 1987-09-30 | 1989-04-06 | University Of Florida | Treatment of hypertension by chronic administration of l-tryptophan or l-5-hydroxytryptophan |
US4837219A (en) * | 1987-11-05 | 1989-06-06 | Jeffrey Hutterer | Medication for Alzheimer's disease |
US5004615A (en) * | 1988-04-27 | 1991-04-02 | Bionix Corporation | Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory |
JP2732109B2 (ja) * | 1989-02-10 | 1998-03-25 | 正樹 今川 | 痴呆治療剤 |
JP2909508B2 (ja) * | 1989-02-14 | 1999-06-23 | マルハ株式会社 | オキアミリン脂質の分取方法 |
US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
JPH02302732A (ja) | 1989-05-18 | 1990-12-14 | Seiko Epson Corp | 液晶表示装置 |
US5401730A (en) * | 1990-07-06 | 1995-03-28 | The Hope Heart Institute | Method for reducing platelet aggregation |
US5077069A (en) | 1991-01-07 | 1991-12-31 | Kabi Pharmacia Ab | Composition of natural antioxidants for the stabilization of polyunsaturated oils |
US5108767A (en) | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
DE4309217A1 (de) * | 1992-01-18 | 1994-07-28 | Margarethe Rabien | Kombinationspräparat Pantothensäure bzw. Dexpanthen + alpha-Liponesäure + Vitamin E (Muskeldystrophie, Polyneuropathie, Muskelatrophie Atoxie, neue Indikation (alpha-Liponsäure + Pantothensäure) Alzheimersche Krankheit |
US5234702A (en) | 1992-03-19 | 1993-08-10 | Abbott Laboratories | Antioxidant system for powdered nutritional products |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
JPH0717855A (ja) | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
DE4304394A1 (en) | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
EP0700303A4 (de) | 1993-05-28 | 1996-08-21 | Abbott Lab | Enterales ernägrungsprodukt |
AU1265295A (en) * | 1993-12-10 | 1995-06-27 | Sami A. Hashim | Reducing likelihood of vascular disorders in susceptible patients |
FR2714574B1 (fr) | 1993-12-31 | 1996-03-15 | Inst Rech Biolog Sa | Nouveaux suppléments alimentaires pour la nutrition des très jeunes enfants. |
JPH07224142A (ja) | 1994-02-08 | 1995-08-22 | Dai Ichi Kogyo Seiyaku Co Ltd | エポキシ樹脂及びエポキシ樹脂組成物 |
NZ281878A (en) | 1994-04-01 | 1997-02-24 | Abbott Lab | Nutritional product for enteral feeding containing indigestible carbohydrate, an oil blend and optionally protein and other nutrients; used to treat colitis |
CA2150741A1 (en) | 1994-06-17 | 1995-12-18 | Susan Trimbo | Pediatric lipid emulsion |
JP3053537B2 (ja) | 1994-11-08 | 2000-06-19 | 株式会社ヤクルト本社 | 脳機能改善剤 |
GB9423625D0 (en) * | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
US5589468A (en) | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
EP0726073A3 (de) * | 1995-02-10 | 1998-07-08 | Eduardo Samuel Bleiweiss | Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten |
JPH08252856A (ja) | 1995-03-16 | 1996-10-01 | Asahi Glass Co Ltd | 樹脂枠体付き窓用板状体の製造装置 |
JPH0954212A (ja) * | 1995-08-11 | 1997-02-25 | Sharp Corp | 位相差フィルム及びその製造方法、並びに液晶表示素子 |
JP3791951B2 (ja) | 1995-11-08 | 2006-06-28 | 株式会社ヤクルト本社 | 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法 |
IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
GB9606736D0 (en) * | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
US5849338A (en) | 1996-04-10 | 1998-12-15 | Chronorx Llc | Unit dosage forms for treatment of vasoconstriction and related conditions |
WO1997039759A2 (en) | 1996-04-24 | 1997-10-30 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
JP3664814B2 (ja) * | 1996-06-26 | 2005-06-29 | 旭化成ケミカルズ株式会社 | 血中脂質改善剤及び食品添加剤 |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
JPH10140919A (ja) | 1996-11-11 | 1998-05-26 | Mika Oosawa | 建物空間内の間仕切り構造 |
ES2179156T3 (es) | 1996-11-20 | 2003-01-16 | Nutricia Nv | Composicion nutricional que incluye grasas para el tratamiento del sindrome metabolico. |
JPH10165119A (ja) * | 1996-12-10 | 1998-06-23 | Seijiro Yanai | イチョウ葉エキス添加強化米及びその製造方法 |
US6013273A (en) | 1997-01-27 | 2000-01-11 | Novartis Nutrition Ag | Treatment of endotoxic shock |
GB9701675D0 (en) | 1997-01-28 | 1997-03-19 | Bridgeman Keith | Composition for the treatment of parkinson's disease |
AU6141498A (en) | 1997-02-04 | 1998-08-25 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
US5843469A (en) * | 1997-04-11 | 1998-12-01 | Mcentee; William J. | Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system |
US6344482B1 (en) | 1997-04-23 | 2002-02-05 | Andrew L. Stoll | Omega-3 fatty acids in the treatment of bipolar disorder |
US5820867A (en) | 1997-04-24 | 1998-10-13 | Bewicke; Calverly M. | General anti-depressant composition for dietary supplement |
AU7222598A (en) | 1997-04-29 | 1998-11-24 | Scotia Holdings Plc | Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants |
FR2762993B1 (fr) | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique |
EP0891719A1 (de) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Narungszusammensetzungen mit Gehalt an Methionin |
GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
AU8925998A (en) | 1997-09-03 | 1999-03-22 | Macro Hi-Tech Jv, Ltd. | Huperzine a derivatives |
EP1032403B1 (de) | 1997-10-24 | 2012-05-02 | John P. Blass | Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
FR2773484B1 (fr) * | 1998-01-09 | 2001-03-30 | Pierre Moreau | Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante |
WO1999036080A1 (en) | 1998-01-13 | 1999-07-22 | Rexall Sundown, Inc. | St. john's wort and methyl donor composition and uses thereof |
AU2470299A (en) | 1998-01-27 | 1999-08-09 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
GB9808579D0 (en) | 1998-04-22 | 1998-06-24 | Novartis Nutrition Ag | Improvements in or relating to organic compounds |
CN1305485A (zh) | 1998-05-04 | 2001-07-25 | 安德里斯·约翰尼斯·凯塞尔 | 单体,寡聚和多聚科诺威纳格尔缩合产物 |
CN1235770A (zh) * | 1998-05-15 | 1999-11-24 | 武汉华凯保健品开发有限公司 | 银杏茶 |
EP1085886A1 (de) | 1998-06-11 | 2001-03-28 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Schutz von neuronen gegen ischämia |
IT1299195B1 (it) | 1998-06-25 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati |
CA2340223A1 (en) | 1998-08-12 | 2000-02-24 | Morinaga Milk Industry Co., Ltd. | Nutritional compositions for preventing or treating hyperlipoproteinemia |
JP2000148134A (ja) | 1998-11-13 | 2000-05-26 | Seiko Epson Corp | 画像表示方法および画像処理装置 |
FR2788437B1 (fr) | 1999-01-14 | 2006-08-11 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle |
US6120814A (en) | 1999-02-22 | 2000-09-19 | Nature's One, Inc. | Organic nutritional formula |
GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
US7208180B2 (en) | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
WO2012058461A1 (en) | 2010-10-29 | 2012-05-03 | C.R.Bard, Inc. | Bioimpedance-assisted placement of a medical device |
-
2000
- 2000-11-02 US US09/703,798 patent/US7226916B1/en not_active Expired - Lifetime
-
2001
- 2001-05-08 CN CNB018124615A patent/CN1245984C/zh not_active Expired - Lifetime
- 2001-05-08 AT AT07120681T patent/ATE431133T1/de active
- 2001-05-08 ES ES09156648T patent/ES2533362T7/es active Active
- 2001-05-08 EP EP20100186257 patent/EP2292210A1/de not_active Withdrawn
- 2001-05-08 DK DK01928256T patent/DK1282365T3/da active
- 2001-05-08 PT PT09156648T patent/PT2070519E/pt unknown
- 2001-05-08 ES ES07120681T patent/ES2326928T3/es not_active Expired - Lifetime
- 2001-05-08 PT PT07120681T patent/PT1911442E/pt unknown
- 2001-05-08 EP EP07120681A patent/EP1911442B1/de not_active Revoked
- 2001-05-08 PT PT01928256T patent/PT1282365E/pt unknown
- 2001-05-08 EP EP01928256A patent/EP1282365B1/de not_active Revoked
- 2001-05-08 CA CA2408032A patent/CA2408032C/en not_active Expired - Lifetime
- 2001-05-08 WO PCT/NL2001/000347 patent/WO2001084961A2/en active IP Right Grant
- 2001-05-08 AT AT01928256T patent/ATE381894T1/de active
- 2001-05-08 ES ES01928256T patent/ES2298232T3/es not_active Expired - Lifetime
- 2001-05-08 DK DK09156648.9T patent/DK2070519T6/en active
- 2001-05-08 DK DK07120681T patent/DK1911442T3/da active
- 2001-05-08 EP EP09156648.9A patent/EP2070519B3/de not_active Expired - Lifetime
- 2001-05-08 AU AU2001255114A patent/AU2001255114A1/en not_active Abandoned
- 2001-05-08 EP EP10186282.9A patent/EP2316426B1/de not_active Revoked
- 2001-05-08 DE DE60132081T patent/DE60132081T2/de not_active Expired - Lifetime
- 2001-05-08 DE DE60138742T patent/DE60138742D1/de not_active Expired - Lifetime
-
2003
- 2003-07-08 HK HK03104859.9A patent/HK1052439B/zh unknown
-
2007
- 2007-04-27 US US11/741,547 patent/US7560447B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 CY CY20081100275T patent/CY1107237T1/el unknown
- 2008-04-14 US US12/102,754 patent/US7772217B2/en not_active Expired - Fee Related
-
2009
- 2009-07-21 CY CY20091100779T patent/CY1109248T1/el unknown
-
2010
- 2010-08-09 US US12/853,001 patent/US8377912B2/en not_active Expired - Lifetime
-
2013
- 2013-02-14 US US13/767,730 patent/US8865687B2/en not_active Expired - Fee Related
-
2015
- 2015-03-24 CY CY20151100298T patent/CY1116212T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001255114A1 (en) | Preparation for the prevention and/or treatment of vascular disorders | |
EP1275399A3 (de) | Präparation zur Vorbeugung und/oder Behandlung von vaskulären Erkrankungen und dazugehörigen sekundären Erkrankungen | |
EP2340824A3 (de) | Verfahren und Zubereitung zur Verringerung der Schwere von ADHD und/oder motorischen Störungen | |
WO2002043659A3 (en) | Composition containing statins and calcium for improved cardiovascular health | |
NZ516101A (en) | Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents | |
AU2003217759A1 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
US20110142967A1 (en) | Method of reducing blood cholesterol and triglyceride levels using combinations of vasoprotective agent | |
CA2531236A1 (en) | Aiding of cognitive function | |
WO2000064276A3 (en) | Enriched spreads | |
WO2002098442A3 (de) | Phytasehaltige zusammensetzung | |
WO2002043662A3 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
EP1325747A3 (de) | Diätergänzung für neuropatischen Patienten | |
US20180311197A1 (en) | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients | |
WO2005040176A3 (en) | Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof | |
US20180280332A1 (en) | Method for improving equilibrioception in healthy individuals and nutritional composition | |
WO2003049668A3 (en) | Method of administering calcium citrate |